ENDPOINTS NEWS4h
De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval
Axsome Therapeutics on Monday reported data for two Phase 3 studies in Alzheimer’s-related agitation, saying one trial ...
ENDPOINTS NEWS3d
FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo
A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been ...
ENDPOINTS NEWS3d
J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app
Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ENDPOINTS NEWS3d
BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties
BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...
ENDPOINTS NEWS3d
WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm
WuXi Apptec will sell its Advanced Technologies unit to the US private equity firm Altaris for an undisclosed amount, a ...
ENDPOINTS NEWS6d
Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?
Novo Nordisk's CagriSema fell short of weight loss goals, causing 17% stock drop. Drug shows similar results to Eli Lilly's ...